MEDI1191, a Novel IL-12 mRNA Therapy for Intratumoral Injection

Time: 10:30 am
day: Day Two


• Understand how IL-12 is a key driver of TH1 responses and anti-tumor immunity, but systemic recombinant IL-12 was poorly tolerated in early clinical trials
• In preclinical models, intratumoral IL-12 mRNA drives IFNγ and CD8+ T cell-dependent anti-tumor immunity that is further enhanced by PD-L1 blockade
• IT MEDI1191 is currently being evaluated in a phase I trial in patients with solid tumors in combination with durvalumab
This seminar will be delivered digitally at the event